Mondello et al. demonstrated in vitro that panobinostat induced mutations in the STAT3 binding site to downregulate mutant-MYD88 transcription, inhibited NF-κB activation, and promoted ibrutinib efficacy in ABC DLBCL cells [128]. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.